Digital Therapeutics for Behavioral Health
The global prevalence of mental health disorders has grown from an estimated 650 million in 1990 to 970 million in 2019. The COVID-19 pandemic exacerbated the issue, with rates of anxiety and depression increasing 25% in the first year of the pandemic. In 2021, global sales of digital therapeutics for behavioral disorders were valued at approximately $625.0m.
Market drivers include the increasing prevalence of mental health disorders worldwide, the rapid expansion of telemedicine during the COVID-19 pandemic, increasing rates of internet access and smartphone penetration, positive regulatory changes for digital therapies, and the cost-effectiveness of digital therapy compared to traditional mental health systems. Limiters to this market include a lack of reimbursement for digital therapies in many world regions, difficulty monitoring patient compliance, slowed clinical trial progress during the COVID-19 pandemic, and the low priority of mental health globally.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for behavioral health digital therapeutics; these include products intended to treat depressive disorder, stress/mild anxiety, anxiety disorder (including more severe conditions such as panic disorder and post-traumatic stress disorder), and substance use disorder (including alcohol and opioid addiction, among others). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26.
Related Medtech Insight articles:
- Digital Health Roundup: Cardio Smart Watches, Pear Therapeutics Own 'Reset,' Agetech Boom
- Happify Health Collaborates With Biogen To Support People Living With Multiple Sclerosis
- Big Health Digital Therapeutics Rings In 2022 With $75M Financing, FDA Alum On Board
- Subscribe to Medtech Insight to view these articles and more!